Expert review
One visit. Multiple experts. One plan.
Six forms of expert review, chosen to fit the case, not one committee that everything is forced through.
Six forms of review
Choose the right room for the case
Molecular tumour board
The core panel reviewing the molecular profile against the clinical picture. Weekly, with a quorum rule.
Organ-specific boards
Fourteen disease-group boards, breast, GI, HPB, thoracic, head & neck, gynae, GU, haematology, neuro, sarcoma, skin, endocrine, paediatric and unknown primary.
Coming soonComplex & rare case board
Difficult, rare or treatment-refractory cases, with external expert input.
Coming soonPaediatric tumour board
Childhood cancers, with paediatric-specific membership and a family-centred pathway.
Coming soonJoint multidisciplinary clinic
Several specialists in one appointment, giving you one consolidated opinion in person.
Coming soonWhite-label virtual board
A partner hospital's own-branded board, powered by KPCIRC, same governance, their name.
Coming soonThe core board
The molecular tumour board
Chaired by Dr Bharat Kwatra and countersigned by the physician clinical lead, who carries clinical responsibility. It meets weekly from launch, even when there are two cases.
The seats
- Chair: Dr Bharat Kwatra
- Head of Computational Precision Oncology. Interpretation strategy, evidence tiering and testing-tier selection.
- Physician clinical lead, co-chair
- Countersigns every recommendation and carries clinical responsibility. No case is decided without this seat filled.
- Genomic interpretation seat
- Presents the variant interpretation, supplied by OnKommon. The quorum rule forbids deciding a case with this seat empty.
- Onco-pathology seat
- Independent review of histopathology and immunohistochemistry, and adequacy assessment for testing.
- Genetic counselling seat
- Flags hereditary risk and triggers the cascade plan for relatives.
- Physician members
- Medical, surgical, radiation and haemato-oncology as the case requires.
- Your referring physician
- May present remotely, and retains clinical responsibility for their patient. We return the patient. Always.
SHOT LATER · IMG-MTB-01 · 1600 × 1200 · 4:3
SHOT LATER · VID-MTB-01 · 3–4 min · the signature asset
What comes out of it
You receive a document. So does your referring doctor, the same day.
The recommended plan
With the clinical and molecular findings it rests on.
The rejected alternatives
And why. A recommendation with no rejected alternatives is an assertion, not a decision.
An evidence tier per option
On-label, off-label and evidence-tiered options distinguished in writing.
The cost of the course
Total-course costing, clinically equivalent cheaper options, and scheme eligibility.
Matched clinical trials
Surfaced from a maintained registry at the decision point, inside the report.
A plain-language version
A separate document your family keeps. Take it to anyone, including someone who disagrees with us.
Before the board sits
No records, no board
A case is not listed until the minimum record set is present. Incomplete cases are held, not opined on, and you are told exactly what is missing, and helped to get it.
The minimum record set
- Histopathology report, and the block or slides where review is needed
- Staging imaging reports, with images where possible
- Current and prior treatment, with dates and doses
- Prior molecular testing, if any
- Current medication and relevant comorbidities
If you do not have all of it
Most people do not. Retrieving a pathology block from the hospital where the diagnosis was made costs Indian families weeks of travel and pleading, and it is why most second opinions are abandoned before they start.
We do the chasing. Block retrieval and records digitisation →
Fourteen disease-group boards, each with its own membership and its own written pathway. These are for cases where the disease-specific question matters more than the molecular one, and most cases go to both.
| Disease group | Sits | What it decides |
|---|---|---|
| Breast | Weekly | Receptor and HER2 interpretation, hereditary risk triage, the onco-fertility trigger, reconstruction sequenced before the first operation. |
| Gastrointestinal | Weekly | Colorectal, gastric, oesophageal and anal. MSI and Lynch cascade, liver-directed strategy, stoma and reversal planning. |
| Hepatobiliary & pancreatic | Fortnightly | Liver reserve, resectability, transplant candidacy, TACE/TARE sequencing against systemic therapy. |
| Thoracic | Weekly | Driver-mutation strategy, re-profiling at progression, CNS surveillance, and the choice between SBRT, ablation and surgery. |
| Head & neck | Weekly | Dental clearance deadlines, feeding-tube timing, speech and swallow rehabilitation, reconstruction. |
| Gynaecologic | Weekly | Cervical, ovarian, uterine and vulvar. Brachytherapy adequacy, germline testing, fertility preservation. |
| Genitourinary | Fortnightly | Prostate, bladder, kidney and testis. Active surveillance criteria, radioligand candidacy, bladder preservation. |
| Haematology | Weekly | Leukaemia, lymphoma and myeloma. CNS prophylaxis, transplant timing, minimal residual disease. |
| Neuro-oncology | Monthly | Primary CNS tumours and brain metastases. The cognitive cost of whole-brain radiation, CNS-penetrant options. |
| Sarcoma & bone | Monthly | Limb-sparing reconstruction, ablation for oligometastatic disease, centre-volume routing. |
| Skin & melanoma | Monthly | Sentinel node strategy, adjuvant immunotherapy, lymphoedema risk and baseline measurement. |
| Endocrine & thyroid | Monthly | Radioiodine indication and dose, and the frequent over-treatment of low-risk disease. |
| Paediatric & adolescent | On listing | Fertility preservation before conditioning, family-centred consent, growth and late-effect planning. |
| Cancer of unknown primary | On listing | Where the molecular profile is the whole diagnostic question and interpretation carries the case. |
Genomic interpretation on every one of these comes through 
, ordered and signed by the oncologist presenting the case. See the site-specific clinics →
Rare histologies, treatment-refractory disease and cancer of unknown primary, with invited sub-specialists and national or international expert linkage where the histology warrants it. Trial and expanded-access searching is part of the workup rather than an afterthought.
Childhood cancers with paediatric-specific membership, age-appropriate consent and assent, family counselling, and schooling and psychosocial support. Any suspected paediatric malignancy is a same-day escalation, not a scheduled referral. Treatment delivery routes to a designated paediatric unit under a named transfer arrangement.
Several specialists participate in one coordinated appointment and give you one consolidated opinion, in person, in the same room. Instead of four appointments in four buildings producing four partial answers.
When it is used
- Complex cancer
- An elderly patient with multiple conditions
- Pre-operative cancer planning
- Treatment sequencing decisions
- Conflicting specialist opinions
- Second opinions where the question spans specialties
A partner hospital's own-branded board, running on our governance, quorum rule and documentation standard. A regional hospital can extend it further to its own satellite and rural sites, becoming the oncology hub in its district. POAS modules M1 and M16 →
The panel
Who sits on the boards
Names are published once credentials, council registration and indemnity are verified, never before.